Earnings
EBIT and EBITDA
Earnings before interest and tax (EBIT) totaled €234.6 million, which was 43.4 percent below the figure for the prior-year period (H1 2021: €414.8 million). EBIT included budgeted purchase price allocation effects amounting to an expense of €45.0 million in the first half of 2022 (H1 2021: expense of €41.8 million). In the reporting period, there were also non-recurring items amounting to a total expense of €32.1 million (H1 2021: expense of €5.5 million) that essentially reflected impairment losses on assets of the Russian subsidiaries.
EBIT adjusted for non-recurring items and purchase price allocation effects (adjusted EBIT) decreased to €311.7 million (H1 2021: €462.2 million). The adjusted EBIT margin fell sharply to 5.6 percent as a result (H1 2021: 9.3 percent).
in € million |
Q2 |
Q2 |
Q1 – Q2 |
in % of revenue |
Q1 – Q2 |
in % of revenue |
---|---|---|---|---|---|---|
EBIT |
116.8 |
221.3 |
234.6 |
4.2% |
414.8 |
8.4% |
Adjustment by functional costs: |
|
|
|
|
|
|
+ Cost of sales |
11.1 |
9.4 |
28.6 |
0.5% |
18.9 |
0.4% |
+ Selling expenses and administrative expenses |
13.3 |
15.1 |
34.4 |
0.6% |
29.5 |
0.6% |
+ Research and development costs |
0.0 |
0.0 |
0.0 |
0.0% |
0.1 |
0.0% |
+ Other costs |
0.2 |
1.4 |
14.2 |
0.3% |
–1.1 |
–0.0% |
Adjusted EBIT |
141.4 |
247.2 |
311.7 |
5.6% |
462.2 |
9.3% |
adjusted for non-recurring items |
1.6 |
5.0 |
32.1 |
0.6% |
5.5 |
0.1% |
adjusted for PPA items |
23.0 |
20.9 |
45.0 |
0.8% |
41.8 |
0.8% |
Earnings before interest, tax, depreciation, and amortization (EBITDA) stood at €739.6 million in the reporting period (H1 2021: €873.9 million). Adjusted EBITDA came to €759.2 million (H1 2021: €879.5 million), giving an adjusted EBITDA margin of 13.7 percent (H1 2021: 17.7 percent).
in € million |
Q2 |
Q2 |
Q1 – Q2 |
in % of revenue |
Q1 – Q2 |
in % of revenue |
---|---|---|---|---|---|---|
EBITDA |
366.5 |
452.7 |
739.6 |
13.4% |
873.9 |
17.6% |
Adjustment by functional costs: |
|
|
|
|
|
|
+ Cost of sales |
0.8 |
0.0 |
8.4 |
0.2% |
0.0 |
0.0% |
+ Selling expenses and administrative expenses |
0.6 |
3.6 |
9.5 |
0.2% |
6.6 |
0.1% |
+ Research and development costs |
0.0 |
0.0 |
0.0 |
0.0% |
0.0 |
0.0% |
+ Other costs |
0.4 |
1.4 |
1.8 |
0.0% |
–1.0 |
–0.0% |
Adjusted EBITDA |
368.2 |
457.7 |
759.2 |
13.7% |
879.5 |
17.7% |
adjusted for non-recurring items |
1.7 |
5.0 |
19.7 |
0.4% |
5.6 |
0.1% |
adjusted for PPA items |
0.0 |
–0.0 |
0.0 |
0.0% |
0.0 |
0.0% |